A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy

Results of a randomized, placebo-controlled phase III study show that duloxetine is an efficacious and well-tolerated intervention for the treatment of taxane- or platinum-related painful chemotherapy-induced peripheral neuropathy. The results were presented by Ellen Lavoie Smith, PhD of the University of Michigan at 2012 ASCO Annual Meeting (1-5 June, Chicago, USA). Read more here.